Literature DB >> 3891304

Transient ischaemic attacks. Current treatment concepts.

C Warlow.   

Abstract

Transient ischaemic attacks are common, having an incidence of at least 50 per 100,000 population per annum, and the risk of stroke and/or death is about 10% per annum. Death is more often due to the complications of coronary artery disease than cerebrovascular disease. The most important issues in management are distinguishing transient ischaemic attacks from several other causes of 'transient focal neurological attacks', and managing the risk factors for vascular disease in general, particularly hypertension. The utility of specific 'antithrombotic' treatments is still uncertain, but for long term use aspirin seems to be the most promising. The only dose so far tested in clinical trials has been about 600mg twice daily but lower doses may theoretically be as, or more, effective. Trials of aspirin and other antiplatelet agents, and also of carotid endarterectomy and extracranial-to-intracranial bypass surgery are continuing and should be strongly encouraged. Although transient ischaemic attacks recover - by definition - in 24 hours, the pathophysiology, natural history, and treatment of focal cerebral ischaemia which recovers in a matter of days or weeks is probably rather similar.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3891304     DOI: 10.2165/00003495-198529050-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  12 in total

1.  LONG-TERM ANTICOAGULANT THERAPY IN TRANSIENT CEREBRAL ISCHAEMIC ATTACKS.

Authors:  J M PEARCE; S S GUBBAY; J N WALTON
Journal:  Lancet       Date:  1965-01-02       Impact factor: 79.321

2.  An evaluation of anticoagulant therapy in the treatment of cerebrovascular disease. Report of the Veterans Administration Cooperative Study of Atherosclerosis, Neruology Section.

Authors: 
Journal:  Neurology       Date:  1961-04       Impact factor: 9.910

3.  Joint study of extracranial arterial occlusion. V. Progress report of prognosis following surgery or nonsurgical treatment for transient cerebral ischemic attacks and cervical carotid artery lesions.

Authors:  W S Fields; V Maslenikov; J S Meyer; W K Hass; R D Remington; M Macdonald
Journal:  JAMA       Date:  1970-03-23       Impact factor: 56.272

4.  Trial of long-term anticoagulant therapy in the treatment of small stroke associated with a normal carotid arteriogram.

Authors:  P Bradshaw; S Brennan
Journal:  J Neurol Neurosurg Psychiatry       Date:  1975-07       Impact factor: 10.154

5.  Controlled trial of aspirin in cerebral ischemia.

Authors:  W S Fields; N A Lemak; R F Frankowski; R J Hardy
Journal:  Stroke       Date:  1977 May-Jun       Impact factor: 7.914

6.  Controlled trial of aspirin in cerebral ischemia. Part II: surgical group.

Authors:  W S Fields; N A Lemak; R F Frankowski; R J Hardy
Journal:  Stroke       Date:  1978 Jul-Aug       Impact factor: 7.914

7.  A randomized trial of aspirin and sulfinpyrazone in threatened stroke.

Authors: 
Journal:  N Engl J Med       Date:  1978-07-13       Impact factor: 91.245

8.  Acetylsalicylic acid in the prevention of stroke in patients with reversible cerebral ischemic attacks. A Danish cooperative study.

Authors:  P S Sorensen; H Pedersen; J Marquardsen; H Petersson; A Heltberg; N Simonsen; O Munck; L A Andersen
Journal:  Stroke       Date:  1983 Jan-Feb       Impact factor: 7.914

9.  Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group.

Authors: 
Journal:  Circulation       Date:  1980-09       Impact factor: 29.690

10.  "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia.

Authors:  M G Bousser; E Eschwege; M Haguenau; J M Lefaucconnier; N Thibult; D Touboul; P J Touboul
Journal:  Stroke       Date:  1983 Jan-Feb       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.